-
Deutsche Bank Reduces Boston Scientific PT To $7.40 (BSX)
Wednesday, February 2, 2011 - 9:36am | 141Deutsche Bank reduced its Boston Scientific (NYSE: BSX) price target to $7.40 from $8.00 in a resaerch report published today. In the report, Deutsche Bank states, "For the past 5 yrs, EPS declined as BSX continues to struggle with consequences of the deal many wished got away. Case stories can be...
-
Boston Scientific Beats - Analyst Blog
Wednesday, February 2, 2011 - 9:35am | 791Boston Scientific Corporation (BSX) reported an EPS of 15 cents during the fourth quarter of fiscal 2010 compared to a loss of 71 cents per share in the year-ago period. However, after considering some adjustments, the EPS was 20 cents, beating the Zacks Consensus Estimate of 10 cents although...
-
Piper Jaffray Raises PT On Covidien To $56
Wednesday, February 2, 2011 - 9:28am | 27Piper Jaffray has raised the price target on Covidien, Ltd. (NYSE: COV) from $53 to $56 and maintains its Overweight rating.
-
Piper Jaffray Raises PT On Kinetic Concepts To $46
Wednesday, February 2, 2011 - 9:26am | 28Piper Jaffray has raised the price target on Kinetic Concepts, Inc. (NYSE: KCI) from $43 to $46 and maintains its Underweight rating.
-
Boston Scientific Beats - Analyst Blog
Wednesday, February 2, 2011 - 9:15am | 791Boston Scientific Corporation (BSX) reported an EPS of 15 cents during the fourth quarter of fiscal 2010 compared to a loss of 71 cents per share in the year-ago period. However, after considering some adjustments, the EPS was 20 cents, beating the Zacks Consensus Estimate of 10 cents although...
-
Citi Leaves Boston Scientific Price Target Of $6.70 Unchanged (BSX)
Wednesday, February 2, 2011 - 8:44am | 101Citi left its Boston Scientific (NYSE: BSX) price target of $6.70 unchanged prior to its conference call with the company this morning, as stated in a research report published today. In the report, Citi states, "4Q10 EPS missed Street views when a $0.05 tax variance and lower R&D spend are...
-
Deutsche Bank Lowers PT On Boston Scientific To $7.40
Wednesday, February 2, 2011 - 8:29am | 27Duetsche Bank has lowered the price target on Boston Scientific (NYSE: BSX) from $8 to $7.40 and maintains its Hold rating.
-
Boston Scientic Reports Better Than Expected Earnings (BSX)
Tuesday, February 1, 2011 - 6:14pm | 197Boston Scientific Corporation (NYSE: BSX) reported earnings of 20 cents per share during the fourth quarter on revenues of $2 billion. Wall Street had expected earnings of 10 cents per share on revenues of $1.99 billion. It also said that it sees first quarter earnings of 7-10 cents per share on...
-
Boston Scientific Corporation Reports Q4 EPS of $.15 vs. $.10; Revenues $2.002B vs. $1.99B
Tuesday, February 1, 2011 - 6:03pm | 45Boston Scientific Corporation (NYSE: BSX) today announced financial results for the fourth quarter and full year ended December 31, 2010. Fourth quarter sales were $2.002 billion with GAAP earnings of $0.15 per diluted share and adjusted earnings per diluted share of $0.20.
-
Cyberonics Announces FDA Approval of Aspire High Capacity Generator
Tuesday, February 1, 2011 - 5:48pm | 74Cyberonics, Inc. (Nasdaq: CYBX) today announced that the AspireHC generator for use in vagus nerve stimulation therapy was approved by the United States Food and Drug Administration (FDA) for commercial release. The AspireHC generator represents the fifth generation of VNS Therapy technology. This...
-
Study Finds Noninvasive Masimo PVI Accurately Predicts Fluid Responsiveness in Intensive Care Patients
Tuesday, February 1, 2011 - 3:54pm | 91Masimo (Nasdaq: MASI) announced today that a new study published in the peer-reviewed journal Critical Care Medicine demonstrates that noninvasive, continuous monitoring of Masimo Pleth Variability Index predicts fluid responsiveness with high sensitivity (95%) and specificity (91%) in mechanically...
-
Hologic Beats Estimates - Analyst Blog
Tuesday, February 1, 2011 - 1:31pm | 466Hologic (HOLX) reported an EPS of 4 cents during the first quarter of fiscal 2011 compared with the year-ago quarter's EPS of 10 cents. However, after adjusting for certain items, EPS was 30 cents, surpassing the Zacks Consensus Estimate by 2 cents and a penny above the year-ago quarter. Revenues...
-
Hologic Beats Estimates - Analyst Blog
Tuesday, February 1, 2011 - 1:00pm | 466Hologic (HOLX) reported an EPS of 4 cents during the first quarter of fiscal 2011 compared with the year-ago quarter's EPS of 10 cents. However, after adjusting for certain items, EPS was 30 cents, surpassing the Zacks Consensus Estimate by 2 cents and a penny above the year-ago quarter. Revenues...
-
C.R. Bard's Mixed 4Q, Profit Zooms - Analyst Blog
Tuesday, February 1, 2011 - 12:07pm | 988Leading medical devices maker C. R. Bard (BCR) reported fourth-quarter fiscal 2010 results after the closing bell on January 31, with an adjusted earnings per share of $1.54 topping the Zacks Consensus Estimate of $1.48 while surpassing the year-ago earnings of $1.39. For fiscal 2010, adjusted...
-
BD Board Declares Dividend of $.41
Tuesday, February 1, 2011 - 11:51am | 47The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 41 cents per common share, payable on March 31, 2011 to holders of record on March 10, 2011. The indicated annual dividend rate is $1.64 per share.